Eventos adversos reportados por Prednisona y Prednisolona al Programa Distrital de Farmacovigilancia en Bogotá D.C, entre el 2009 al 31 de Agosto de 2017
SUMMARY The drugs subject of pharmacovigilance study by the authors are prednisolone and prednisone, synthetic corticosteroids derived from cortisol, widely used for various specialties due to their high efficacy and benefits in many medical situations exerting their actions as immunosuppressants an...
- Autores:
-
Martínez Tinjacá, Jaris Paola
Gamboa Jiménez, Ana Silvia
- Tipo de recurso:
- Trabajo de grado de pregrado
- Fecha de publicación:
- 2017
- Institución:
- Universidad de Ciencias Aplicadas y Ambientales U.D.C.A
- Repositorio:
- Repositorio Institucional UDCA
- Idioma:
- spa
- OAI Identifier:
- oai:repository.udca.edu.co:11158/856
- Acceso en línea:
- https://repository.udca.edu.co/handle/11158/856
- Palabra clave:
- Corticoides
Prednisona
Prednisolona
Reacciones adversas
Antiinflamatorios
Síndrome de Cusing
Osteoporosis
Diabetes mellitus
Prednisolona -- Efectos secundarios
Prednisona -- Efectos secundarios
Medicamentos -- Efectos secundarios
- Rights
- closedAccess
- License
- Derechos Reservados - Universidad de Ciencias Aplicadas y Ambientales
id |
RepoUDCA2_0ddc40ada03191bbdfe871f6e50d8678 |
---|---|
oai_identifier_str |
oai:repository.udca.edu.co:11158/856 |
network_acronym_str |
RepoUDCA2 |
network_name_str |
Repositorio Institucional UDCA |
repository_id_str |
|
dc.title.spa.fl_str_mv |
Eventos adversos reportados por Prednisona y Prednisolona al Programa Distrital de Farmacovigilancia en Bogotá D.C, entre el 2009 al 31 de Agosto de 2017 |
title |
Eventos adversos reportados por Prednisona y Prednisolona al Programa Distrital de Farmacovigilancia en Bogotá D.C, entre el 2009 al 31 de Agosto de 2017 |
spellingShingle |
Eventos adversos reportados por Prednisona y Prednisolona al Programa Distrital de Farmacovigilancia en Bogotá D.C, entre el 2009 al 31 de Agosto de 2017 Corticoides Prednisona Prednisolona Reacciones adversas Antiinflamatorios Síndrome de Cusing Osteoporosis Diabetes mellitus Prednisolona -- Efectos secundarios Prednisona -- Efectos secundarios Medicamentos -- Efectos secundarios |
title_short |
Eventos adversos reportados por Prednisona y Prednisolona al Programa Distrital de Farmacovigilancia en Bogotá D.C, entre el 2009 al 31 de Agosto de 2017 |
title_full |
Eventos adversos reportados por Prednisona y Prednisolona al Programa Distrital de Farmacovigilancia en Bogotá D.C, entre el 2009 al 31 de Agosto de 2017 |
title_fullStr |
Eventos adversos reportados por Prednisona y Prednisolona al Programa Distrital de Farmacovigilancia en Bogotá D.C, entre el 2009 al 31 de Agosto de 2017 |
title_full_unstemmed |
Eventos adversos reportados por Prednisona y Prednisolona al Programa Distrital de Farmacovigilancia en Bogotá D.C, entre el 2009 al 31 de Agosto de 2017 |
title_sort |
Eventos adversos reportados por Prednisona y Prednisolona al Programa Distrital de Farmacovigilancia en Bogotá D.C, entre el 2009 al 31 de Agosto de 2017 |
dc.creator.fl_str_mv |
Martínez Tinjacá, Jaris Paola Gamboa Jiménez, Ana Silvia |
dc.contributor.advisor.spa.fl_str_mv |
Sabogal Carmona, Juan Sebastián, dir. |
dc.contributor.author.spa.fl_str_mv |
Martínez Tinjacá, Jaris Paola Gamboa Jiménez, Ana Silvia |
dc.subject.spa.fl_str_mv |
Corticoides Prednisona Prednisolona Reacciones adversas Antiinflamatorios Síndrome de Cusing Osteoporosis Diabetes mellitus |
topic |
Corticoides Prednisona Prednisolona Reacciones adversas Antiinflamatorios Síndrome de Cusing Osteoporosis Diabetes mellitus Prednisolona -- Efectos secundarios Prednisona -- Efectos secundarios Medicamentos -- Efectos secundarios |
dc.subject.lemb.spa.fl_str_mv |
Prednisolona -- Efectos secundarios Prednisona -- Efectos secundarios Medicamentos -- Efectos secundarios |
description |
SUMMARY The drugs subject of pharmacovigilance study by the authors are prednisolone and prednisone, synthetic corticosteroids derived from cortisol, widely used for various specialties due to their high efficacy and benefits in many medical situations exerting their actions as immunosuppressants and anti-inflammatories. study since in clinical practice it is evident that these drugs are sometimes used indiscriminately, without taking into account the pathology to be treated, its severity, duration of treatment, its metabolization and / or adequate characteristics of the drug, since This drug is prescribed in complex pathologies (lupus erythematosus, rheumatoid arthritis, prostate cancer) and often require chronic use, as it is known that the action of a drug can be altered, by the action of food, by the same disease, by characteristics unique to the patient, by interaction with other medications or by the prolonged use of them, producing adverse effects, some with more incidence than others and that can even reach death. For the development of this project, a cross-sectional descriptive study of the data of adverse events to prednisolone or prednisone reported to the Bogotá district health program was carried out. The variables described were related to factors of person, time, place and those of Adverse events, for the period under study from 2009 to August 31, 2017. The results obtained from the District Pharmacovigilance program in Bogotá were grouped taking into account variables such as age, gender, ADR, causality, severity and severity, PRM, therapeutic failure among others. The pharmacovigilance reports related to the prednisolone and prednisone drugs, represented 236 cases in which the majority of adverse reactions were caused to female patients between the age range of 50 - 54 years and greater than 75, most of the adverse reactions were They related symptoms such as headache, Rash, Cushing syndrome, drowsiness, dizziness, infection, erythema, pain, among others, and a small portion due to more severe reactions such as kidney failure and diabetes; symptoms related to the literature, and that occur during therapy or even after the treatment has ended. Likewise it was found that 10% of the reports corresponded to problems related to medications, many of these cases were due to errors at the time of dispensing, problems of the places destined to the delivery of the medication due to confusing the prescribed dose, human errors that they should be minimized to the maximum to ensure that the patient receives the appropriate medication in the proper dose. It is considered highly significant to initiate processes aimed at raising awareness among patients, as well as the medical team taking into account that these should be responsible for encouraging and motivating the patient, as well as being receptive to the information provided by patients within the treatment. verbal or written for the purpose of obtaining timely information about the adverse events that could occur due to the consumption of these medications. To assist with the training and awareness of the pharmacological monitoring process, it will be attached as Annex 1. An educational poster, with information concerning the possible adverse events and symptoms that each patient could present when using the medication in order to optimize the use of the group of medicines and provide the correct and necessary care to be able to watch over and preserve the patient's health |
publishDate |
2017 |
dc.date.issued.spa.fl_str_mv |
2017 |
dc.date.accessioned.spa.fl_str_mv |
2018-03-01T14:31:12Z |
dc.date.available.spa.fl_str_mv |
2018-03-01T14:31:12Z |
dc.type.spa.fl_str_mv |
Trabajo de grado - Pregrado |
dc.type.coarversion.fl_str_mv |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
dc.type.coar.spa.fl_str_mv |
http://purl.org/coar/resource_type/c_7a1f |
dc.type.driver.spa.fl_str_mv |
info:eu-repo/semantics/bachelorThesis |
dc.type.version.spa.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.redcol.spa.fl_str_mv |
http://purl.org/redcol/resource_type/TP |
format |
http://purl.org/coar/resource_type/c_7a1f |
status_str |
publishedVersion |
dc.identifier.uri.spa.fl_str_mv |
https://repository.udca.edu.co/handle/11158/856 |
url |
https://repository.udca.edu.co/handle/11158/856 |
dc.language.iso.spa.fl_str_mv |
spa |
language |
spa |
dc.rights.spa.fl_str_mv |
Derechos Reservados - Universidad de Ciencias Aplicadas y Ambientales |
dc.rights.coar.fl_str_mv |
http://purl.org/coar/access_right/c_14cb |
dc.rights.uri.spa.fl_str_mv |
https://creativecommons.org/licenses/by-nc/4.0/ |
dc.rights.accessrights.spa.fl_str_mv |
info:eu-repo/semantics/closedAccess |
dc.rights.creativecommons.spa.fl_str_mv |
Atribución-NoComercial 4.0 Internacional (CC BY-NC 4.0) |
rights_invalid_str_mv |
Derechos Reservados - Universidad de Ciencias Aplicadas y Ambientales https://creativecommons.org/licenses/by-nc/4.0/ Atribución-NoComercial 4.0 Internacional (CC BY-NC 4.0) http://purl.org/coar/access_right/c_14cb |
eu_rights_str_mv |
closedAccess |
dc.format.spa.fl_str_mv |
pdf |
dc.coverage.spatial.spa.fl_str_mv |
Bogotá, Colombia |
dc.publisher.faculty.spa.fl_str_mv |
Facultad de Ciencias |
dc.publisher.program.spa.fl_str_mv |
Química Farmacéutica |
institution |
Universidad de Ciencias Aplicadas y Ambientales U.D.C.A |
bitstream.url.fl_str_mv |
https://repository.udca.edu.co/bitstreams/aa7186c7-c11e-4643-b450-7f834238d17f/download https://repository.udca.edu.co/bitstreams/fce44268-491d-4bb6-9f11-dfe5f3c4c1c1/download https://repository.udca.edu.co/bitstreams/5cc2f2dd-1fc7-4335-a71f-fe870fe14190/download https://repository.udca.edu.co/bitstreams/77646f3f-5f3e-4985-9f50-87d882e86b98/download |
bitstream.checksum.fl_str_mv |
d798813b81072454e5f798fa8bb3a9e5 38a2a7ff9f1ab6d669609e863f85bae3 8a4605be74aa9ea9d79846c1fba20a33 737181d0edb996b6ffb6c2a764e06218 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 |
repository.name.fl_str_mv |
Repositorio - Universidad de Ciencias Aplicadas y Ambientales UDCA. |
repository.mail.fl_str_mv |
bdigital@metabiblioteca.com |
_version_ |
1814213242798473216 |
spelling |
Sabogal Carmona, Juan Sebastián, dir.Martínez Tinjacá, Jaris PaolaGamboa Jiménez, Ana SilviaBogotá, Colombia2018-03-01T14:31:12Z2018-03-01T14:31:12Z2017https://repository.udca.edu.co/handle/11158/856SUMMARY The drugs subject of pharmacovigilance study by the authors are prednisolone and prednisone, synthetic corticosteroids derived from cortisol, widely used for various specialties due to their high efficacy and benefits in many medical situations exerting their actions as immunosuppressants and anti-inflammatories. study since in clinical practice it is evident that these drugs are sometimes used indiscriminately, without taking into account the pathology to be treated, its severity, duration of treatment, its metabolization and / or adequate characteristics of the drug, since This drug is prescribed in complex pathologies (lupus erythematosus, rheumatoid arthritis, prostate cancer) and often require chronic use, as it is known that the action of a drug can be altered, by the action of food, by the same disease, by characteristics unique to the patient, by interaction with other medications or by the prolonged use of them, producing adverse effects, some with more incidence than others and that can even reach death. For the development of this project, a cross-sectional descriptive study of the data of adverse events to prednisolone or prednisone reported to the Bogotá district health program was carried out. The variables described were related to factors of person, time, place and those of Adverse events, for the period under study from 2009 to August 31, 2017. The results obtained from the District Pharmacovigilance program in Bogotá were grouped taking into account variables such as age, gender, ADR, causality, severity and severity, PRM, therapeutic failure among others. The pharmacovigilance reports related to the prednisolone and prednisone drugs, represented 236 cases in which the majority of adverse reactions were caused to female patients between the age range of 50 - 54 years and greater than 75, most of the adverse reactions were They related symptoms such as headache, Rash, Cushing syndrome, drowsiness, dizziness, infection, erythema, pain, among others, and a small portion due to more severe reactions such as kidney failure and diabetes; symptoms related to the literature, and that occur during therapy or even after the treatment has ended. Likewise it was found that 10% of the reports corresponded to problems related to medications, many of these cases were due to errors at the time of dispensing, problems of the places destined to the delivery of the medication due to confusing the prescribed dose, human errors that they should be minimized to the maximum to ensure that the patient receives the appropriate medication in the proper dose. It is considered highly significant to initiate processes aimed at raising awareness among patients, as well as the medical team taking into account that these should be responsible for encouraging and motivating the patient, as well as being receptive to the information provided by patients within the treatment. verbal or written for the purpose of obtaining timely information about the adverse events that could occur due to the consumption of these medications. To assist with the training and awareness of the pharmacological monitoring process, it will be attached as Annex 1. An educational poster, with information concerning the possible adverse events and symptoms that each patient could present when using the medication in order to optimize the use of the group of medicines and provide the correct and necessary care to be able to watch over and preserve the patient's healthLos fármacos sujetos a estudio de farmacovigilancia por los autores son prednisolona y prednisona, corticosteroides sintéticos derivados del cortisol, ampliamente utilizados para diversas especialidades debido a su alta eficacia y beneficios en muchas situaciones médicas que ejercen su acciones como inmunosupresores y anti-inflamatorios. estudio puesto que en la práctica clínica es evidente que estas drogas se utilizan a veces indiscriminadamente, sin tener en cuenta la patología a tratar, su severidad, duración del tratamiento, su metabolización y/o características adecuadas de la droga, puesto que esta droga se prescribe en patologías complejas (eritematoso de lupus, artritis reumatoide, cáncer de próstata) y requieren a menudo el uso crónico, pues se sabe que la acción de un medicamento puede ser alterada, por la acción del alimento, por la misma enfermedad, por características único para el paciente, por interacción con otros medicamentos o por el uso prolongado de los mismos, produciendo efectos adversos, algunos con más incidencia que otros y que incluso pueden llegar a la muerte. Para el desarrollo de este proyecto, se realizó un estudio descriptivo transversal de los datos de eventos adversos a prednisolona o prednisona reportados al programa de salud del distrito de Bogotá. Las variables descritas se relacionaron con factores de persona, tiempo, lugar y los de eventos adversos, para el período bajo estudio de 2009 a 31 de agosto de 2017. Los resultados obtenidos del programa de farmacovigilancia del distrito en Bogotá se agruparon teniendo en cuenta variables como la edad, género, ADR, causalidad, severidad y severidad, PRM, fracaso terapéutico entre otros. Los informes de la farmacovigilancia relacionados con las drogas de la prednisolona y de la prednisona, representaron 236 casos en los cuales la mayoría de reacciones adversas fueron causadas a los pacientes femeninos entre la gama de edad de 50-54 años y mayor que 75, la mayor parte de las reacciones adversas se relacionaron con síntomas como dolor de cabeza, erupción cutánea, síndrome de Cushing, somnolencia, mareos, infección, eritema, dolor, entre otros, y una pequeña porción debido a reacciones más severas como la insuficiencia renal y la diabetes; los síntomas relacionados con la literatura, y que ocurren durante la terapia o incluso después de que el tratamiento ha terminado. Asimismo se encontró que el 10% de los informes correspondían a problemas relacionados con medicamentos, muchos de estos casos se debieron a errores en el momento de la dispensación, problemas de los lugares destinados a la entrega del medicamento debido a la confusión de la dosis prescrita, humanos errores que deben minimizarse al máximo para asegurar que el paciente reciba el medicamento apropiado en la dosis apropiada. Se considera altamente significativo iniciar procesos dirigidos a sensibilizar a los pacientes, así como al equipo médico teniendo en cuenta que éstos deben ser responsables de estimular y motivar al paciente, además de ser receptivo a la información proporcionada por los pacientes dentro del tratamiento. verbal o escrita con el propósito de obtener información oportuna sobre los eventos adversos que podrían ocurrir debido al consumo de estos medicamentos. Para contribuir a la formación y sensibilización del proceso de seguimiento farmacológico, se anexará como anexo 1. Un póster educativo, con información sobre los posibles eventos adversos y síntomas que cada paciente pudiera presentar al utilizar la medicación para optimizar el uso del grupo de medicamentos y proporcionar la atención correcta y necesaria para poder observar y preservar la salud del pacientePregradoQuímico(a) FarmacéuticopdfspaDerechos Reservados - Universidad de Ciencias Aplicadas y Ambientaleshttps://creativecommons.org/licenses/by-nc/4.0/info:eu-repo/semantics/closedAccessAtribución-NoComercial 4.0 Internacional (CC BY-NC 4.0)http://purl.org/coar/access_right/c_14cbCorticoidesPrednisonaPrednisolonaReacciones adversasAntiinflamatoriosSíndrome de CusingOsteoporosisDiabetes mellitusPrednisolona -- Efectos secundariosPrednisona -- Efectos secundariosMedicamentos -- Efectos secundariosEventos adversos reportados por Prednisona y Prednisolona al Programa Distrital de Farmacovigilancia en Bogotá D.C, entre el 2009 al 31 de Agosto de 2017Trabajo de grado - Pregradohttp://purl.org/coar/resource_type/c_7a1finfo:eu-repo/semantics/bachelorThesisinfo:eu-repo/semantics/publishedVersionhttp://purl.org/redcol/resource_type/TPhttp://purl.org/coar/version/c_970fb48d4fbd8a85Facultad de CienciasQuímica FarmacéuticaPublicationTEXTEVENTOS ADVERSOS REPORTADOS POR PREDNISONA Y PREDNISOLONA AL PROGRAMA DISTRITAL DE FARMACOVIGILAN.pdf.txtEVENTOS ADVERSOS REPORTADOS POR PREDNISONA Y PREDNISOLONA AL PROGRAMA DISTRITAL DE FARMACOVIGILAN.pdf.txtExtracted texttext/plain207672https://repository.udca.edu.co/bitstreams/aa7186c7-c11e-4643-b450-7f834238d17f/downloadd798813b81072454e5f798fa8bb3a9e5MD53THUMBNAILEVENTOS ADVERSOS REPORTADOS POR PREDNISONA Y PREDNISOLONA AL PROGRAMA DISTRITAL DE FARMACOVIGILAN.pdf.jpgEVENTOS ADVERSOS REPORTADOS POR PREDNISONA Y PREDNISOLONA AL PROGRAMA DISTRITAL DE FARMACOVIGILAN.pdf.jpgGenerated Thumbnailimage/jpeg4090https://repository.udca.edu.co/bitstreams/fce44268-491d-4bb6-9f11-dfe5f3c4c1c1/download38a2a7ff9f1ab6d669609e863f85bae3MD54LICENSElicense.txtlicense.txttext/plain; charset=utf-81748https://repository.udca.edu.co/bitstreams/5cc2f2dd-1fc7-4335-a71f-fe870fe14190/download8a4605be74aa9ea9d79846c1fba20a33MD52ORIGINALEVENTOS ADVERSOS REPORTADOS POR PREDNISONA Y PREDNISOLONA AL PROGRAMA DISTRITAL DE FARMACOVIGILAN.pdfEVENTOS ADVERSOS REPORTADOS POR PREDNISONA Y PREDNISOLONA AL PROGRAMA DISTRITAL DE FARMACOVIGILAN.pdfapplication/pdf2553828https://repository.udca.edu.co/bitstreams/77646f3f-5f3e-4985-9f50-87d882e86b98/download737181d0edb996b6ffb6c2a764e06218MD5111158/856oai:repository.udca.edu.co:11158/8562024-05-09 14:25:09.057https://creativecommons.org/licenses/by-nc/4.0/Derechos Reservados - Universidad de Ciencias Aplicadas y Ambientalesopen.accesshttps://repository.udca.edu.coRepositorio - Universidad de Ciencias Aplicadas y Ambientales UDCA.bdigital@metabiblioteca.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 |